Systematic review: The role of liver transplantation in the management of hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 10, 2012, Pages 1113-1134

  Maggs, J R L ^a   Suddle, A R ^a   Aluvihare, V ^a   Heneghan, M A ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; MITOMYCIN C; PLACEBO;

ADJUVANT THERAPY; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DATA BASE; DISEASE SURVEILLANCE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; ORGAN DONOR; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT INDICATION; TUMOR GROWTH; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; WAITING LISTS;

EID: 84859902982     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05072.x     Document Type: Review

References (127)

1. Haug CE, Jenkins RL, Rohrer RJ, et al,. Liver transplantation for primary hepatic cancer. Transplantation 1992; 53: 376-82.
2. Selby R, Kadry Z, Carr B, Tzakis A, Madariaga JR, Iwatsuki S,. Liver transplantation for hepatocellular carcinoma. World J Surg 1995; 19: 53-8.
3. Yokoyama I, Todo S, Iwatsuki S, Starzl TE,. Liver transplantation in the treatment of primary liver cancer. Hepatogastroenterology 1990; 37: 188-93. (Pubitemid 20162253)
4. Onaca N, Davis GL, Jennings LW, Goldstein RM, Klintmalm GB,. Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2009; 15: 574-80.
5. Pichlmayr R, Weimann A, Steinhoff G, Ringe B,. Liver transplantation for hepatocellular carcinoma: clinical results and future aspects. Cancer Chemother Pharmacol 1992; 31 (Suppl.): S157-61.
6. Ojogho ON, So SK, Keeffe EB, et al,. Orthotopic liver transplantation for hepatocellular carcinoma. Factors affecting long-term patient survival. Arch Surg 1996; 131: 935-9.
7. Mazzaferro V, Regalia E, Doci R, et al,. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9. (Pubitemid 26079803)
8. Cabrera R, Nelson DR,. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 31: 461-76.
9. Singal A, Volk ML, Waljee A, et al,. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47.
10. Cabrera R, Pannu DS, Caridi J, et al,. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 2011; 34: 205-13.
11. Pinter M, Sieghart W, Hucke F, et al,. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011; 34: 949-59.
12. Hollebecque A, Cattan S, Romano O, et al,. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther 2011; 34: 1193-201.
13. Cabibbo G, Genco C, Di Marco V, et al,. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Aliment Pharmacol Ther 2011; 34: 196-204.
14. Grossman EJ, Millis JM,. Liver transplantation for non-hepatocellular carcinoma malignancy: indications, limitations, and analysis of the current literature. Liver Transpl 2010; 16: 930-42.
15. Shin WY, Suh KS, Lee HW, et al,. Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2010; 16: 678-84.
16. Roayaie S, Schwartz JD, Sung MW, et al,. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534-40. (Pubitemid 38443593)
17. Colella G, De Carlis L, Rondinara GF, et al,. Is hepatocellular carcinoma in cirrhosis an actual indication for liver transplantation? Transplant Proc 1997; 29: 492-4. (Pubitemid 27123501)
18. Chui AK, Rao AR, McCaughan GW, et al,. An active liver transplant programme for hepatocellular carcinoma in cirrhotic patients: is it justified? Clin Transplant 1999; 13: 531-5. (Pubitemid 30011432)
19. Chen JW, Kow L, Verran DJ, et al,. Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in HCC in Australia and New Zealand. HPB (Oxford) 2009; 11: 81-9.
20. Llovet JM, Fuster J, Bruix J,. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-40.
21. Borie F, Bouvier AM, Herrero A, et al,. Treatment and prognosis of hepatocellular carcinoma: a population based study in France. J Surg Oncol 2008; 98: 505-9.
22. Toso C, Kneteman NM, James Shapiro AM, Bigam DL,. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int 2009; 22: 869-75.
23. Mazzaferro V, Llovet JM, Miceli R, et al,. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
24. Chan EY, Larson AM, Fix OK, et al,. Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl 2008; 14: 956-65. (Pubitemid 352003894)
25. Parfitt JR, Marotta P, Alghamdi M, et al,. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007; 13: 543-51. (Pubitemid 46605857)
26. Iwatsuki S, Dvorchik I, Marsh JW, et al,. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 2000; 191: 389-94.
27. Herrero JI, Sangro B, Quiroga J, et al,. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 2001; 7: 631-6. (Pubitemid 32677888)
28. Yao FY, Ferrell L, Bass NM, et al,. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-403. (Pubitemid 32496976)
29. Llovet JM, Paradis V, Kudo M, Zucman-Rossi J,. Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transpl 2011; 17: S67-71.
30. Villanueva A, Hoshida Y, Battiston C, et al,. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011; 140: 1501-12.
31. Schwartz M, Dvorchik I, Roayaie S, et al,. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol 2008; 49: 581-8.
32. Adler M, De Pauw F, Vereerstraeten P, et al,. Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system. Liver Transpl 2008; 14: 526-33. (Pubitemid 351524409)
33. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP,. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007; 7: 2587-96. (Pubitemid 47561609)
34. Duffy JP, Vardanian A, Benjamin E, et al,. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246: 502-9. (Pubitemid 47312148)
35. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, et al,. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006; 12: 1761-9. (Pubitemid 44911801)
36. Raj A, McCall J, Gane E,. Validation of the "Metroticket" predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma. J Hepatol 2011; 55: 1063-8.
37. Toso C, Trotter J, Wei A, et al,. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008; 14: 1107-15.
38. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM,. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49: 832-8.
39. Herrero JI, Sangro B, Pardo F, et al,. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl 2008; 14: 272-8. (Pubitemid 351425478)
40. Sugawara Y, Tamura S, Makuuchi M,. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 2007; 25: 310-2. (Pubitemid 350014958)
41. Silva M, Moya A, Berenguer M, et al,. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl 2008; 14: 1449-60.
42. Jonas S, Mittler J, Pascher A, et al,. Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center. Liver Transpl 2007; 13: 896-903. (Pubitemid 46939443)
43. Lee SG, Hwang S, Moon DB, et al,. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008; 14: 935-45. (Pubitemid 352003892)
44. Ito T, Takada Y, Ueda M, et al,. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 2007; 13: 1637-44.
45. Takada Y, Ito T, Ueda M, et al,. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis 2007; 25: 299-302. (Pubitemid 350014956)
46. Soejima Y, Taketomi A, Yoshizumi T, et al,. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 2007; 83: 893-9. (Pubitemid 46682729)
47. Zheng SS, Xu X, Wu J, et al,. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008; 85: 1726-32.
48. Kwon CH, Kim DJ, Han YS, et al,. HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis 2007; 25: 313-9. (Pubitemid 350014959)
49. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
50. DuBay D, Sandroussi C, Sandhu L, et al,. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011; 253: 166-72.
51. Silva MA, Hegab B, Hyde C, Guo B, Buckels JAC, Mirza DF,. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008; 57: 1592-6.
52. Bargellini I, Vignali C, Cioni R, et al,. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria-selection parameter for liver transplantation. Radiology 2010; 255: 289-300.
53. Otto G, Herber S, Heise M, et al,. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-7. (Pubitemid 44194595)
54. Vitale A, D'Amico F, Frigo AC, et al,. Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol 2010; 17: 2290-302.
55. Yamamoto J, Iwatsuki S, Kosuge T, et al,. Should hepatomas be treated with hepatic resection or transplantation? Cancer 1999; 86: 1151-8. (Pubitemid 29446996)
56. Shabahang M, Franceschi D, Yamashiki N, et al,. Comparison of hepatic resection and hepatic transplantation in the treatment of hepatocellular carcinoma among cirrhotic patients. Ann Surg Oncol 2002; 9: 881-6. (Pubitemid 35265639)
57. Margarit C, Escartin A, Castells L, Vargas V, Allende E, Bilbao I,. Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl 2005; 11: 1242-51. (Pubitemid 41511939)
58. Ringe B, Pichlmayr R, Wittekind C, Tusch G,. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991; 15: 270-85.
59. Baccarani U, Isola M, Adani GL, et al,. Superiority of transplantation versus resection for the treatment of small hepatocellular carcinoma. Transpl Int 2008; 21: 247-54. (Pubitemid 351197349)
60. Moon DB, Lee SG, Hwang S,. Liver transplantation for hepatocellular carcinoma: single nodule with Child-Pugh class A sized less than 3 cm. Dig Dis 2007; 25: 320-8. (Pubitemid 350014960)
61. Otto G, Heuschen U, Hofmann WJ, Krumm HG, Hinz U, Herfarth C,. Is transplantation really superior to resection in the treatment of small hepatocellular carcinoma? Transplant Proc 1997; 29: 489-91. (Pubitemid 27123500)
62. Bigourdan JM, Jaeck D, Meyer N, et al,. Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus transplantation. Liver Transpl 2003; 9: 513-20. (Pubitemid 36621722)
63. Fan HL, Chen TW, Hsieh CB, et al,. Liver transplantation is an alternative treatment of hepatocellular carcinoma beyond the Milan criteria. Am J Surg 2010; 200: 252-7.
64. Poon RT, Fan ST, Lo CM, Liu CL, Wong J,. Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg 2007; 245: 51-8. (Pubitemid 46035435)
65. Vennarecci G, Ettorre GM, Antonini M, et al,. First-line liver resection and salvage liver transplantation are increasing therapeutic strategies for patients with hepatocellular carcinoma and child a cirrhosis. Transplant Proc 2007; 39: 1857-60. (Pubitemid 47198834)
66. Hwang S, Lee SG, Moon DB, et al,. Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma. Liver Transpl 2007; 13: 741-6. (Pubitemid 46796546)
67. Ng KK, Lo CM, Liu CL, Poon RT, Chan SC, Fan ST,. Survival analysis of patients with transplantable recurrent hepatocellular carcinoma: implications for salvage liver transplant. Arch Surg 2008; 143: 68-74. (Pubitemid 351159293)
68. Kim BW, Park YK, Kim YB, Wang HJ, Kim MW,. Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: feasibility of the Milan criteria and operative risk. Transplant Proc 2008; 40: 3558-61.
69. Del Gaudio M, Ercolani G, Ravaioli M, et al,. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant 2008; 8: 1177-85. (Pubitemid 351763682)
70. Cherqui D, Laurent A, Mocellin N, et al,. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 2009; 250: 738-46.
71. Scatton O, Zalinski S, Terris B, et al,. Hepatocellular carcinoma developed on compensated cirrhosis: resection as a selection tool for liver transplantation. Liver Transpl 2008; 14: 779-88. (Pubitemid 351899426)
72. Tanaka H, Kubo S, Tsukamoto T, et al,. Recurrence rate and transplantability after liver resection in patients with hepatocellular carcinoma who initially met transplantation criteria. Transplant Proc 2005; 37: 1254-6. (Pubitemid 40590854)
73. Poon RT, Fan ST, Lo CM, Liu CL, Ng IO, Wong J,. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 2000; 18: 1094-101. (Pubitemid 30123788)
74. Cucchetti A, Vitale A, Gaudio MD, et al,. Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma. Am J Transplant 2010; 10: 619-27.
75. Lu DSK, Yu NC, Raman SS, et al,. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005; 234: 954-60. (Pubitemid 40250843)
76. Chen M-S, Li J-Q, Zheng Y, et al,. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-8. (Pubitemid 43327762)
77. Livraghi T, Meloni F, Di Stasi M, et al,. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008; 47: 82-9. (Pubitemid 351171044)
78. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L,. Local recurrence after hepatic radiofrequency coagulation: multivariate analysis and review of contributing factors. Ann Surg 2005; 242: 158-71. (Pubitemid 41033431)
79. Llovet JM, Bruix J,. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42. (Pubitemid 36152543)
80. Kirikoshi H, Saito S, Yoneda M, et al,. Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. Hepatol Res 2009; 39: 553-62.
81. Pelletier SJ, Fu S, Thyagarajan V, et al,. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl 2009; 15: 859-68.
82. Llovet JM, Mas X, Aponte JJ, et al,. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50: 123-8. (Pubitemid 34028315)
83. Lesurtel M, Mullhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA,. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006; 6: 2644-50. (Pubitemid 44571684)
84. Mazzaferro V, Battiston C, Perrone S, et al,. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004; 240: 900-9. (Pubitemid 39425785)
85. Perez Saborido B, Meneu JC, Moreno E, Garcia I, Moreno A, Fundora Y,. Is transarterial chemoembolization necessary before liver transplantation for hepatocellular carcinoma? Am J Surg 2005; 190: 383-7. (Pubitemid 41139290)
86. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al,. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005; 11: 767-75. (Pubitemid 40975578)
87. Frangakis C, Geschwind JF, Kim D, et al,. Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list. Cardiovasc Intervent Radiol 2011; 34: 1254-61.
88. Yao FY, Kinkhabwala M, LaBerge JM, et al,. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant 2005; 5: 795-804. (Pubitemid 40461290)
89. Sandroussi C, Dawson LA, Lee M, et al,. Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transpl Int 2010; 23: 299-306.
90. Lord R, Suddle A, Ross PJ,. Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies. Int J Clin Pract 2011; 65: 182-8.
91. Hoffmann K, Glimm H, Radeleff B, et al,. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation-HeiLivCa [ISRCTN24081794]. BMC Cancer 2008; 8: 349.
92. Vitale A, Volk ML, Pastorelli D, et al,. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 2010; 51: 165-73.
93. Chapman WC, Majella Doyle MB, Stuart JE, et al,. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008; 248: 617-25.
94. Ravaioli M, Grazi GL, Piscaglia F, et al,. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008; 8: 2547-57.
95. Yao FY, Kerlan RK, Jr, Hirose R, et al,. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48: 819-27.
96. De Luna W, Sze DY, Ahmed A, et al,. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant 2009; 9: 1158-68.
97. Jang JW, You CR, Kim CW, et al,. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther 2010; 31: 415-23.
98. Graziadei IW, Sandmueller H, Waldenberger P, et al,. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9: 557-63. (Pubitemid 36701690)
99. Hsieh CB, Chou SJ, Shih ML, et al,. Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2008; 34: 906-10.
100. Pokorny H, Gnant M, Rasoul-Rockenschaub S, et al,. Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant 2005; 5: 788-94. (Pubitemid 40461289)
101. Bernal E, Montero JL, Delgado M, et al,. Adjuvant chemotherapy for prevention of recurrence of invasive hepatocellular carcinoma after orthotopic liver transplantation. Transplant Proc 2006; 38: 2495-8. (Pubitemid 44693709)
102. Soderdahl G, Backman L, Isoniemi H, et al,. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int 2006; 19: 288-94.
103. Chen Z-N, Mi L, Xu J, et al,. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys 2006; 65: 435-44.
104. Xu J, Shen ZY, Chen XG, et al,. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007; 45: 269-76. (Pubitemid 46374583)
105. Kneteman NM, Oberholzer J, Al Saghier M, et al,. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301-11. (Pubitemid 39406087)
106. Chinnakotla S, Davis GL, Vasani S, et al,. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009; 15: 1834-42.
107. Zimmerman MA, Trotter JF, Wachs M, et al,. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14: 633-8. (Pubitemid 351696274)
108. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM,. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237-43.
109. Schnitzbauer AA, Zuelke C, Graeb C, et al,. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10: 190.
110. Ioannou GN, Perkins JD, Carithers RL, Jr,. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008; 134: 1342-51. (Pubitemid 351615357)
111. Vitale A, Volk ML, Gambato M, et al,. Estimation of the harm to the waiting list as a crucial factor in the selection of patients with hepatocellular carcinoma for liver transplantation. Transplant Proc 2010; 42: 1194-6.
112. Piscaglia F, Camaggi V, Ravaioli M, et al,. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. Liver Transpl 2007; 13: 857-66. (Pubitemid 46947850)
113. Freeman RB, Edwards EB, Harper AM,. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 2006; 6: 1416-21. (Pubitemid 44030324)
114. Washburn K, Edwards E, Harper A, Freeman R,. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010; 10: 1643-8.
115. Hwang S, Lee SG, Joh JW, Suh KS, Kim DG,. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005; 11: 1265-72. (Pubitemid 41511942)
116. Di Sandro S, Slim AO, Giacomoni A, et al,. Living donor liver transplantation for hepatocellular carcinoma: long-term results compared with deceased donor liver transplantation. Transplant Proc 2009; 41: 1283-5.
117. Vakili K, Pomposelli JJ, Cheah YL, et al,. Living donor liver transplantation for hepatocellular carcinoma: increased recurrence but improved survival. Liver Transpl 2009; 15: 1861-6.
118. Chao SD, Roberts JP, Farr M, Yao FY,. Short waitlist time does not adversely impact outcome following liver transplantation for hepatocellular carcinoma. Am J Transplant 2007; 7: 1594-600. (Pubitemid 46776249)
119. Fernandez JA, Robles R, Marin C, et al,. Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? Transplant Proc 2003; 35: 1818-20. (Pubitemid 37093723)
120. Lohe F, Angele MK, Gerbes AL, Lohrs U, Jauch KW, Schauer RJ,. Tumour size is an important predictor for the outcome after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2005; 31: 994-9. (Pubitemid 41671113)
121. Muscari F, Foppa B, Kamar N, Peron JM, Selves J, Suc B,. Liberal selection criteria for liver transplantation for hepatocellular carcinoma. Br J Surg 2009; 96: 785-91.
122. Santoyo J, Sanchez B, de la Mata M, et al,. Liver transplantation for hepatocellular carcinoma: results of a multicenter study with common priorization criteria. Transplant Proc 2009; 41: 1009-11.
123. Gabrielli M, Vivanco M, Hepp J, et al,. Liver transplantation results for hepatocellular carcinoma in Chile. Transplant Proc 2010; 42: 299-301.
124. Hayashi PH, Ludkowski M, Forman LM, et al,. Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation. Am J Transplant 2004; 4: 782-7. (Pubitemid 38637578)
125. Maddala YK, Stadheim L, Andrews JC, et al,. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 2004; 10: 449-55. (Pubitemid 38380323)
126. Lu DS, Yu NC, Raman SS, et al,. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41: 1130-7. (Pubitemid 40593921)
127. Bharat A, Brown DB, Crippin JS, et al,. Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg 2006; 203: 411-20. (Pubitemid 44416253)